Role of epigallocatechin gallate on aluminum exposure-induced bone damage via NLRP3 inflammasome signaling pathway.

Authors

Fatma Betul Yoladi, Saziye Sezin Palabiyik-Yucelik, Zekai Halici, Elif Cadirci, Alptug Atila

Published in

Molecular biology reports. Volume 53. Issue 1. Jul 01, 2026. Epub Jul 01, 2026.

Abstract

Aluminum (Al) residue in the ecosystem has been increasing significantly, making Al exposure inevitable. Al has been shown to inhibit bone formation and cause osteoporosis. Epigallocatechin gallate (EGCG), which is one of the primary polyphenols found in green tea, has shown positive impacts on bone health; however, its possible therapeutic role in preventing Al-induced bone damage remains insufficiently explored. The study aimed to examine the effect of EGCG on Al-induced bone damage possibly through modulation of the NLRP3 inflammasome pathway.
Rats were exposed to AlCl₃ to induce bone damage and treated with different doses of EGCG. Bone and serum mineral levels were determined using biochemical analyses. Relative mRNA expression levels of NLRP3, caspase-1, IL-1β, OPN, and OCN in bone tissue were evaluated by RT-PCR analysis and bone IL-1β levels were determined by ELISA.
AlCl₃ exposure increased Al accumulation and serum Ca levels in rat bones, while decreasing bone Ca levels. It also induced bone damage through the activation of the NLRP3/caspase-1/IL-1β pathway. EGCG treatment resulted in dose-dependent recovery of these parameters. AlCl₃ exposure significantly increased OPN mRNA expression, while OCN mRNA expression showed a non-significant decreasing tendency. EGCG treatment was associated with reduced OPN mRNA expression and a tendency toward increased OCN mRNA expression.
These findings suggest that Al-induced bone damage may be associated with activation of the NLRP3 inflammasome pathway and that EGCG may exert protective effects, through modulation of this pathway. Thus, it was concluded that EGCG may be a promising protective agent for preventing Al-induced bone damage and may serve as a potential preventive agent for the treatment of bone diseases.

PMID:
42384287
Bibliographic data and abstract were imported from PubMed on 01 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.